Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
Phthalimide analogs for antimalarial drug discovery
Malaria remains one of the world's most life-threatening diseases and, thus, it is a major
public health concern all around the world. The disease can become devastating if not …
public health concern all around the world. The disease can become devastating if not …
How I treat relapsed multiple myeloma
E Kastritis, E Terpos… - Blood, The Journal of the …, 2022 - ashpublications.org
Despite recent advances, multiple myeloma remains an incurable disease for most patients,
and initial remission will be followed by relapses requiring therapy. For many, there will be …
and initial remission will be followed by relapses requiring therapy. For many, there will be …
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a …
C Thomas, S Ailawadhi, R Popat, D Kleinman… - Frontiers in …, 2023 - frontiersin.org
Introduction Newer treatment options for relapsed/refractory multiple myeloma (RRMM) with
efficacy and safety profiles that differ from traditional therapies have facilitated personalized …
efficacy and safety profiles that differ from traditional therapies have facilitated personalized …
[PDF][PDF] 泊马度胺在复发/难治性多发性骨髓瘤中的研究进展
任立伟， 吴涛， 王宗慧， 白海 - 临床血液学杂志, 2022 - lcxyen.whuhzzs.com
多发性骨髓瘤是一类恶性浆细胞克隆性疾病, 是血液系统中第二大常见恶性肿瘤,
目前仍不能完全治愈. 随着治疗药物的更新换代, 近年来患者用药后的反应率和生存率都有了 …
目前仍不能完全治愈. 随着治疗药物的更新换代, 近年来患者用药后的反应率和生存率都有了 …
Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
In the backdrop of rapidly changing relapsed/refractory (RR) multiple myeloma (MM)
treatment schema that mainly evolves around immunotherapies, it is easy to disregard more …
treatment schema that mainly evolves around immunotherapies, it is easy to disregard more …
The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma
Y Liu, B Li, X Chen, H Xiong… - Expert Review of …, 2024 - Taylor & Francis
ABSTRACT Introduction Immunomodulatory drugs (IMiDs) are widely used in the
management of newly diagnosed and relapsed/refractory multiple myeloma patients. These …
management of newly diagnosed and relapsed/refractory multiple myeloma patients. These …
[PDF][PDF] The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic …
KY Liao, Y Liu, H Xiong, XM Chen… - European Review for …, 2022 - europeanreview.org
OBJECTIVE: Triplet regimens based on pomalidomide and dexamethasone have been
applied to treat relapsed/refractory multiple myeloma, but the safety and efficacy are not yet …
applied to treat relapsed/refractory multiple myeloma, but the safety and efficacy are not yet …
[PDF][PDF] 多发性骨髓瘤发病机制及治疗的研究进展
王盼盼 - 中国医学创新, 2023 - zgyxcx.com
多发性骨髓瘤(multiple myeloma, MM) 是克隆性浆细胞异常增殖性疾病, 发病机制复杂,
具有高度异质性. 染色体易位, 非整倍体, 基因突变, 骨髓微环境和表观遗传学异常是疾病发生和 …
具有高度异质性. 染色体易位, 非整倍体, 基因突变, 骨髓微环境和表观遗传学异常是疾病发生和 …
[HTML][HTML] 硼替佐米、 泊马度胺、 地塞米松方案治疗复发/难治性多发性骨髓瘤的疗效及安全性
王俊， 许宏， 初晓霞， 王伟 - Chinese Journal of Hematology, 2023 - ncbi.nlm.nih.gov
多发性骨髓瘤(MM) 是一种浆细胞恶性肿瘤, 尽管目前存在多种治疗方式, MM
仍是一种不能被治愈的疾病, 几乎所有患者均会经历复发难治阶段, 新药如免疫调节剂(IMiD) …
仍是一种不能被治愈的疾病, 几乎所有患者均会经历复发难治阶段, 新药如免疫调节剂(IMiD) …